Effects of neonatal anti-delta antibody treatment on the murine immune system. II. Functional capacity of a stable sIgM+sIa+sIgD- B cell population.
Mice were injected from birth with rabbit anti-mouse IgD (RaM delta). Studies in the accompanying paper indicated that the B cells from these mice have a stable sIgM+sIa+sIgD- B cell population. In the studies presented herein the in vivo and in vitro antibody responses of these mice were examined as well as their responsiveness to various B cell mitogens. The results indicate that splenic B cells from RaM delta-suppressed mice differ from normal adult murine splenic B cells by failure to express increased sIa antigen after in vitro stimulation with soluble anti-mu antibodies and failure to proliferate in response to in vitro stimulation with either soluble or Sepharose-bound anti-mu antibody. Nevertheless, these mice generate relatively normal in vivo IgM and IgG antibody responses to TI-2 and to both high and low epitope density forms of TD antigens as well as secondary IgG antibody responses to a TD antigen. In addition, B cells from RaM delta-treated mice generate relatively normal primary in vitro IgM antibody responses to TI-1, TI-2, and TD antigens. These data suggest that sIgD- B cells can produce antibody responses to the majority of antigenic signals even though they appear to lack one or more differentiative pathways.
D000818:Animals; D000888:Antibodies, Anti-Idiotypic / Q000276:immunology*; D000917:Antibody Formation; D000954:Antigens, Surface / Q000032:analysis*; D001402:B-Lymphocytes / Q000276:immunology*; D005260:Female; D007072:Immunoglobulin D / Q000032:analysis* / Q000276:immunology; D007075:Immunoglobulin M / Q000032:analysis*; D008070:Lipopolysaccharides / Q000494:pharmacology; D008213:Lymphocyte Activation / Q000187:drug effects; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C
D000888:Antibodies, Anti-Idiotypic; D000954:Antigens, Surface; D007072:Immunoglobulin D; D007075:Immunoglobulin M; D008070:Lipopolysaccharides